Adakveo - direct healthcare professional communication (DHPC)

Crizanlizumab

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC) : Adakveo (crizanlizumab): Phase III study (CSEG101A2301) shows no superiority of crizanlizumab over placebo

Key facts

• Medicine name:
  Adakveo
• Active substance:
  Crizanlizumab
• Therapeutic area (MeSH):
  Anemia, Sickle Cell
• Procedure number:
  EMEA/H/C/004874
• DHPC type:
  Referral - Article 20 procedure
• Human ATC codes:
  B06AX01
• Dissemination date:
  14/02/2023